Welcome to our dedicated page for Bright Minds Biosciences SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.
The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.
Bright Minds Biosciences Inc. is calling its annual general meeting of shareholders for March 31, 2026 in Vancouver at 10:00 a.m. Pacific Time. Shareholders will receive the audited consolidated financial statements for the year ended September 30, 2025, vote on electing six directors (including one new nominee, Steve Farr), and appoint De Visser Gray LLP as auditor with remuneration set by the board. The company is using Canadian notice-and-access rules, so proxy materials and the management information circular are available online, with paper copies on request. Shareholders of record on February 10, 2026, when 9,787,161 common shares were outstanding, may vote by internet, phone, mail or in person, with a proxy deadline of March 27, 2026.
Bright Minds Biosciences Inc. has filed details for its upcoming Annual General Meeting of security holders. The record date for notice, voting, and beneficial ownership determination is set for February 10, 2026, meaning holders of common shares on that date will be entitled to participate.
The Annual General Meeting is scheduled for March 31, 2026 in Vancouver. The company will use notice-and-access for both registered and beneficial holders, and it will not send proxy materials directly to NOBOs or pay for delivery to OBOs, indicating that intermediaries will handle most material distribution.
Bright Minds Biosciences Inc. reported that it will present at the Jefferies Global Healthcare Conference on June 3, 2026 at 4:20 p.m. EDT, with a live and archived webcast available through its investor website for 30 days.
The Company also granted stock options to directors, officers and consultants to purchase an aggregate of 109,000 common shares under its share option plan. The options are exercisable at US$83.40 per share for five years and vest in four equal annual installments of 25%, starting on the first anniversary of the grant date.
BRIGHT MINDS BIOSCIENCES INC. Schedule 13G discloses that Vestal Point Capital and Ryan Wilder report beneficial ownership of 492,319 shares of Common Shares, representing 5% of the class. The percentage is calculated using 9,787,161 Common Shares outstanding as of February 12, 2026 as stated in the filing. The filing shows shared voting and shared dispositive power over the reported shares and states the shares are held on behalf of the Vestal Point Fund and Account.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 1,284,324 shares of Bright Minds Biosciences Inc. (CUSIP 10919W405), representing 13.1% of the class as of 03/31/2026. The filing states the shares are held in multiple managed portfolios for which Janus Henderson is ultimate parent; the Asset Managers exercise shared voting and dispositive power over 1,284,324 shares but disclaim rights to dividends or sale proceeds. The disclosure names Janus Henderson Biotech Innovation Master Fund Ltd. as a managed portfolio holding more than 5% and notes an irrevocable delegation of investment and voting discretion affecting reporting status. The filing is signed by a compliance officer on 5/15/2026.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 1,284,324 shares of Bright Minds Biosciences Inc. representing 13.1% of the class. The filing states the Asset Managers have shared voting and shared dispositive power over these shares and that the Managed Portfolios hold rights to dividends and sale proceeds. The filing identifies Janus Henderson Biotech Innovation Master Fund Ltd. as a Managed Portfolio holding more than 5% and notes an irrevocable delegation of investment and voting discretion affecting reporting status. The Schedule is signed by Kristin Mariani on 5/15/2026.
Bright Minds Biosciences Inc. ownership update: Vivo Opportunity entities amended beneficial ownership reporting to show combined holdings of certain Vivo funds and general partners. Vivo Opportunity Fund Holdings, L.P. (via Vivo Opportunity, LLC) holds 504,645 shares of Common Stock, representing 5.2% of the class. Vivo Opportunity Cayman Fund, L.P. (via Vivo Opportunity Cayman, LLC) holds 52,527 shares, representing 0.5%. The filing cites 9,787,161 shares outstanding as of February 12, 2026. All reported shares are held of record by the named partnership entities and voting and dispositive powers are stated as sole for each reported amount.
Bright Minds Biosciences Inc. Schedule 13G/A shows Cormorant Asset Management, LP and Bihua Chen report shared beneficial ownership of 950,000 common shares, representing 9.71% of the class. The filing states 9,787,161 Common Shares outstanding as of February 12, 2026. The shares are held through Cormorant Global Healthcare Master Fund, LP and reported as shared voting and dispositive power.
Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen, reported an open-market sale of 109,331 common shares of Bright Minds Biosciences Inc. at $89.50 per share.
After this transaction, the reporting structure shows 950,000 common shares indirectly held. The reporting persons, including Cormorant Asset Management and Bihua Chen, disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest.